Insertion and 3-year follow-up experience of 372 etonogestrel subdermal contraceptive implants by family physicians in Granada, Spain
BACKGROUND: User profile, continuation rate, reasons for discontinuation, problems during insertion and removal, and effectiveness of an etonogestrel subdermal contraceptive implant (ESCI) were assessed.
STUDY DESIGN: A follow-up of 372 women 3 years after insertion of an ESCI performed by family physicians in Granada, Spain, by means of consultations, examination of medical records and telephone interviews.
RESULTS: Data were available for 356 (95.7%) women. The average age was 27.2 years, and 159 (42.7%) were nulliparous. Continuation rates were 91.0% at 1 year, 74.7% at 2 years and 65.1% at 2 years and 9 months. The main reasons for discontinuation were excessive bleeding (44, 12.4%), wish to become pregnant (44, 12.4%) and side effects not related to menstruation (21, 5.9%). However, 141 (39.6%) received a second implant when the first one expired. No pregnancy occurred in 893.4 women-years.
CONCLUSIONS: Family physicians can achieve excellent results with the ESCI. It should be included in the range of contraceptives offered by primary care physicians.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:80 |
|---|---|
| Enthalten in: |
Contraception - 80(2009), 5 vom: 19. Nov., Seite 457-62 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arribas-Mir, Lorenzo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
304GTH6RNH |
|---|
| Anmerkungen: |
Date Completed 22.02.2010 Date Revised 20.11.2014 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.contraception.2009.04.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM19211042X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM19211042X | ||
| 003 | DE-627 | ||
| 005 | 20231223192349.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2009 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.contraception.2009.04.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0640.xml |
| 035 | |a (DE-627)NLM19211042X | ||
| 035 | |a (NLM)19835720 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arribas-Mir, Lorenzo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Insertion and 3-year follow-up experience of 372 etonogestrel subdermal contraceptive implants by family physicians in Granada, Spain |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2010 | ||
| 500 | |a Date Revised 20.11.2014 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: User profile, continuation rate, reasons for discontinuation, problems during insertion and removal, and effectiveness of an etonogestrel subdermal contraceptive implant (ESCI) were assessed | ||
| 520 | |a STUDY DESIGN: A follow-up of 372 women 3 years after insertion of an ESCI performed by family physicians in Granada, Spain, by means of consultations, examination of medical records and telephone interviews | ||
| 520 | |a RESULTS: Data were available for 356 (95.7%) women. The average age was 27.2 years, and 159 (42.7%) were nulliparous. Continuation rates were 91.0% at 1 year, 74.7% at 2 years and 65.1% at 2 years and 9 months. The main reasons for discontinuation were excessive bleeding (44, 12.4%), wish to become pregnant (44, 12.4%) and side effects not related to menstruation (21, 5.9%). However, 141 (39.6%) received a second implant when the first one expired. No pregnancy occurred in 893.4 women-years | ||
| 520 | |a CONCLUSIONS: Family physicians can achieve excellent results with the ESCI. It should be included in the range of contraceptives offered by primary care physicians | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Contraceptive Agents, Female |2 NLM | |
| 650 | 7 | |a Drug Implants |2 NLM | |
| 650 | 7 | |a etonogestrel |2 NLM | |
| 650 | 7 | |a 304GTH6RNH |2 NLM | |
| 650 | 7 | |a Desogestrel |2 NLM | |
| 650 | 7 | |a 81K9V7M3A3 |2 NLM | |
| 700 | 1 | |a Rueda-Lozano, Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Agrela-Cardona, María |e verfasserin |4 aut | |
| 700 | 1 | |a Cedeño-Benavides, Tania |e verfasserin |4 aut | |
| 700 | 1 | |a Olvera-Porcel, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Bueno-Cavanillas, Aurora |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Contraception |d 1972 |g 80(2009), 5 vom: 19. Nov., Seite 457-62 |w (DE-627)NLM000108367 |x 1879-0518 |7 nnns |
| 773 | 1 | 8 | |g volume:80 |g year:2009 |g number:5 |g day:19 |g month:11 |g pages:457-62 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.contraception.2009.04.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 80 |j 2009 |e 5 |b 19 |c 11 |h 457-62 | ||